# BIONCaRT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioncart

- Industry: Biotechnology
- Headquarters: Leipzig, Germany
- Website: www.bioncart.com
- Latest round: Seed (Aug 14, 2024)
- Investors on record: 2

## About

BIONCaRT GmbH, based in Leipzig, Germany, is a biopharmaceutical company focused on developing innovative cell-based therapies, particularly for regenerative medicine applications.Founded in 2017, BIONCaRT GmbH specializes in biopharmaceutical innovations, focusing on cell-based therapies derived from mesenchymal stromal cells (MSCs). The company has completed one deal, with its most recent transaction occurring on August 14, 2024. Specifics about the founder's prior ventures are not available.BIONCaRT GmbH specializes in the development and manufacture of biopharmaceuticals, primarily focusing on cell-based therapeutic products derived from mesenchymal stromal cells (MSCs) for clinical applications in humans. The company's flagship product, MesemCart, is an allogeneic cell therapy aimed at treating focal cartilage defects in the knee joint. This innovative therapy utilizes MSCs harvested from the umbilical cord tissue of healthy newborns, which are ex vivo expanded and embedded in a collagen-based matrix. The treatment aims to promote cartilage repair, reduce inflammation, and alleviate pain, addressing significant unmet medical needs for patients suffering from moderate to severe cartilage damage. BIONCaRT's products primarily target markets in Germany and broader Europe, particularly within the orthopedic and regenerative medicine sectors, catering to healthcare providers, hospitals, and ultimately patients in need of effective therapeutic solutions.The revenue model for BIONCaRT GmbH is principally structured around B2B transactions, focusing on partnerships with healthcare providers and institutions for the distribution of its therapeutic products. The company engages in clinical studies to validate the efficacy and safety of its offerings, which subsequently support the marketing authorization applications. Given the specialized nature of its flagship product, MesemCart, revenue generation is facilitated through fixed-price agreements or contracts with hospitals and clinics that participate in clinical trials and subsequent procurement of approved products. The commercial strategy anticipates revenue growth from the launch of its products in the German market in 2027, followed by broader European expansion post Phase III trials.In August 2024, BIONCaRT GmbH raised an undisclosed amount of Seed funding from new investors Bm-t and Technologiegruenderfonds Sachsen, with participation from other unspecified investors. The company will use the funding to conduct the clinical trial of the allogeneic cell therapy in Europe and to prepare the market launch of the product in Germany and Europe. BIONCaRT GmbH's strategic plan includes the upcoming launch of MesemCart, targeting the German market in 2027 and expanding into broader European markets following the completion of Phase III trials.

## Funding rounds

- Seed, Aug 14, 2024 — CFH Management, Bm-t

## Investors

- CFH Management (https://capitalatlas.ai/funds/cfh-management) — Seed
- Bm-t (https://capitalatlas.ai/funds/bm-t) — Seed